Accolade (NASDAQ:ACCD) Announces Quarterly Earnings Results

Accolade (NASDAQ:ACCD) issued its quarterly earnings data on Friday. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01, Zacks reports. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%.

Accolade Trading Down 0.4 %

NASDAQ ACCD opened at $6.83 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.72 and a quick ratio of 2.72. The company has a market capitalization of $550.07 million, a price-to-earnings ratio of -6.63 and a beta of 2.08. Accolade has a 12 month low of $3.08 and a 12 month high of $15.21. The company’s fifty day moving average price is $3.73 and its two-hundred day moving average price is $3.82.

Insiders Place Their Bets

In other news, CEO Rajeev Singh sold 13,357 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total value of $48,085.20. Following the completion of the transaction, the chief executive officer now directly owns 814,316 shares in the company, valued at $2,931,537.60. This trade represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 40,881 shares of company stock valued at $144,987 over the last 90 days. 8.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ACCD. Stifel Nicolaus reissued a “hold” rating and set a $7.03 price objective (down previously from $8.00) on shares of Accolade in a research note on Thursday. Leerink Partners restated a “market perform” rating on shares of Accolade in a research report on Wednesday. Barclays dropped their price target on shares of Accolade from $5.50 to $5.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 9th. Stephens reduced their price target on shares of Accolade from $10.00 to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 9th. Finally, Morgan Stanley lowered their price objective on Accolade from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Ten research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.55.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.